S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
NYSE:TAK

Takeda Pharmaceutical (TAK) Stock Price, News & Analysis

$14.19
-0.20 (-1.39%)
(As of 03/27/2024 ET)
Today's Range
$14.18
$14.37
50-Day Range
$13.92
$14.87
52-Week Range
$13.19
$17.15
Volume
1.71 million shs
Average Volume
1.54 million shs
Market Capitalization
$44.91 billion
P/E Ratio
21.50
Dividend Yield
3.66%
Price Target
$22.00

Takeda Pharmaceutical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
55.0% Upside
$22.00 Price Target
Short Interest
Healthy
0.18% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.65mentions of Takeda Pharmaceutical in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$30 M Sold Last Quarter
Proj. Earnings Growth
-16.67%
From $1.50 to $1.25 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.04 out of 5 stars

Medical Sector

207th out of 939 stocks

Pharmaceutical Preparations Industry

84th out of 431 stocks

TAK stock logo

About Takeda Pharmaceutical Stock (NYSE:TAK)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

TAK Stock Price History

TAK Stock News Headlines

the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Takeda staying in Kendall Square
Championing Rare Voices on Rare Disease Day
5 Best Japanese Stocks To Buy In 2024
Q4 2023 Halozyme Therapeutics Inc Earnings Call
See More Headlines
Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/01/2024
Today
3/28/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
5/09/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
49,095
Year Founded
1781

Price Target and Rating

Average Stock Price Target
$22.00
High Stock Price Target
$30.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+55.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$2.35 billion
Pretax Margin
3.72%

Debt

Sales & Book Value

Annual Sales
$29.81 billion
Cash Flow
$3.60 per share
Book Value
$14.86 per share

Miscellaneous

Outstanding Shares
3,164,800,000
Free Float
3,163,534,000
Market Cap
$44.91 billion
Optionable
Optionable
Beta
0.54

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Christophe Weber (Age 58)
    President, CEO & Representative Director
    Comp: $3.84M
  • Mr. Constantine Saroukos (Age 53)
    CFO & Representative Director
    Comp: $2.39M
  • Dr. Andrew S. Plump (Age 59)
    President of Research & Development and Representative Director
    Comp: $2.74M
  • Dr. Seigo Izumo
    Chair of Management Board
  • Mr. Haruhiko Hirate (Age 67)
    Member of Management Board
  • Mr. Salvatore Alesci M.D. (Age 49)
    Ph.D., Member of Management Board and Head of R&D Global Science & Biomedical Policy
  • Norimasa Takeda
    Chief Accounting Officer & Corporate Controller
  • Mr. Iwaaki Taniguchi
    Senior Vice President of Corporate Finance & Controlling Department
  • Mr. Gabriele Ricci (Age 46)
    Chief Data & Technology Officer
  • Mr. Christopher David O'Reilly
    Global Head of Investor Relations & Global Finance

Should I Buy Takeda Pharmaceutical Stock? TAK Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Takeda Pharmaceutical was last updated on Tuesday, March 26, 2024 at 10:42 PM.

Pros

Here are some ways that investors could benefit from investing in Takeda Pharmaceutical Company Limited:

  • Takeda Pharmaceutical has a diverse portfolio of pharmaceutical products in areas such as gastroenterology, rare diseases, oncology, and neuroscience, providing revenue stability and growth potential.
  • The company has engaged in numerous collaborations and licensing agreements with prominent biotech and pharmaceutical companies, enhancing its research and development capabilities and potentially leading to innovative product launches.
  • Recent financial disclosures show that Takeda Pharmaceutical has a market capitalization of $46.11 billion, indicating its position as a significant player in the pharmaceutical industry.
  • Takeda Pharmaceutical's stock price has shown stability with a price-to-earnings ratio of 22.08, suggesting a balanced valuation compared to industry peers.
  • The company's global presence, with operations in Japan and internationally, provides geographic diversification and exposure to various healthcare markets.

Cons

Investors should be bearish about investing in Takeda Pharmaceutical Company Limited for these reasons:

  • The pharmaceutical industry is highly competitive and subject to regulatory challenges, which could impact Takeda Pharmaceutical's product development pipeline and market access.
  • Despite collaborations, the company's debt-to-equity ratio of 0.64 may raise concerns about its financial leverage and ability to manage debt obligations effectively.
  • Takeda Pharmaceutical's one year low and high stock price range of $13.19 to $17.15 indicates volatility in its share price, potentially leading to uncertainty for investors.
  • The company's PEG ratio of 3.28 suggests a higher valuation relative to its earnings growth rate, which could be a concern for investors looking for undervalued opportunities.
  • Hedge funds and institutional investors owning a significant portion of Takeda Pharmaceutical's stock (2.65%) may influence stock price movements and limit individual investor influence.

TAK Stock Analysis - Frequently Asked Questions

Should I buy or sell Takeda Pharmaceutical stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TAK shares.
View TAK analyst ratings
or view top-rated stocks.

What is Takeda Pharmaceutical's stock price target for 2024?

1 equities research analysts have issued 1 year target prices for Takeda Pharmaceutical's stock. Their TAK share price targets range from $14.00 to $30.00. On average, they predict the company's stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 55.0% from the stock's current price.
View analysts price targets for TAK
or view top-rated stocks among Wall Street analysts.

How have TAK shares performed in 2024?

Takeda Pharmaceutical's stock was trading at $14.27 at the beginning of the year. Since then, TAK stock has decreased by 0.6% and is now trading at $14.19.
View the best growth stocks for 2024 here
.

Are investors shorting Takeda Pharmaceutical?

Takeda Pharmaceutical saw a drop in short interest in the month of February. As of February 29th, there was short interest totaling 6,260,000 shares, a drop of 21.7% from the February 14th total of 7,990,000 shares. Based on an average daily trading volume, of 1,880,000 shares, the short-interest ratio is currently 3.3 days. Currently, 0.2% of the shares of the company are sold short.
View Takeda Pharmaceutical's Short Interest
.

When is Takeda Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our TAK earnings forecast
.

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Company Limited (NYSE:TAK) issued its earnings results on Thursday, February, 1st. The company reported $0.51 EPS for the quarter. The firm had revenue of $7.52 billion for the quarter. Takeda Pharmaceutical had a net margin of 6.90% and a trailing twelve-month return on equity of 12.57%.

Is Takeda Pharmaceutical a good dividend stock?

Takeda Pharmaceutical (NYSE:TAK) pays an annual dividend of $0.52 per share and currently has a dividend yield of 3.63%. The dividend payout ratio is 78.79%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, TAK will have a dividend payout ratio of 41.60% next year. This indicates that the company will be able to sustain or increase its dividend.

What ETFs hold Takeda Pharmaceutical's stock?
What guidance has Takeda Pharmaceutical issued on next quarter's earnings?

Takeda Pharmaceutical updated its FY 2023 earnings guidance on Thursday, February, 1st. The company provided earnings per share (EPS) guidance of 3.030-3.030 for the period. The company issued revenue guidance of $26.9 billion-$26.9 billion.

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (0.45%), Goldman Sachs Group Inc. (0.14%), Goldman Sachs Group Inc. (0.14%), Brandes Investment Partners LP (0.08%), Northern Trust Corp (0.06%) and Managed Asset Portfolios LLC (0.06%).
View institutional ownership trends
.

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Takeda Pharmaceutical have any subsidiaries?
The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.
Read More
This page (NYSE:TAK) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners